IPM Brief – Issue 12 | The Yes Is Not the Finish Line

Happy Thursday.

Health systems love a yes.

A medicine is approved. A report is published. A committee is reshuffled. A reform is announced. A digital tool is reimbursed. A company invests. A politician promises cheaper insulin. A regulator says the burden has been reduced.

Then the hard part begins.

This week’s brief is about what happens after the yes. Europe has produced its first joint clinical assessments, but patients still face national access clocks. Brussels is preparing to trade Parliament jobs, but health needs commitments, not chairs. A CDC nominee promised scientific integrity, but the test is whether doctors will confront power when evidence is under pressure. Medical-device rules are being eased, but simplification cannot become a quiet downgrade of safety. A breast-cancer drug was approved, then the launch delay swallowed the headline. Digital care met the fraud wall. A biomarker opened the door in Australia, but patients are still paying.

The lesson is blunt: progress is not the announcement. Progress is whether the system can deliver.

• Europe’s Parliament is reshuffling power. Will health make the cut? Brussels is preparing for its midterm power trade. Committee chairs, coordinators and political posts will shape the files that decide whether personalised medicine becomes routine care.
• One assessment. Twenty-seven access clocks? Europe’s first joint clinical assessments for tarlatamab and lurbinectedin are a milestone. But one shared evidence base is not the same as one timely route to treatment.
• Doctors must get their hands dirty. The CDC hearing exposed a hard question for clinical leaders everywhere: is it enough to know the science, or must doctors be willing to fight for it?
• EU eases clinical leaders everywhere: is it enough to know the science, or must doctors be willing to MDR burden for well-established medical devices. The Commission is recalibrating device rules for mature technologies. Proportionate regulation matters, but simplification must not become deregulation by another name.
• The launch delay ate the approval. Celcuity’s breast-cancer drug won FDA approval, then investors focused on supply, timing and label concerns. Approval was the yes. Launch is the proof.
• Digital care met the fraud wall. CMS is tightening remote patient monitoring rules. Digital health has to prove it is care, not just another billing machine.
• The biomarker said yes. The subsidy said wait. In Australia, rare-cancer patients are still paying huge sums while Keytruda’s broader PBS listing remains unfinished. Tumour-agnostic science has hit reimbursement reality.
• Pipeline rich, pathway poor. Latin America is attracting trials and medicines. The real question is whether public systems can turn that pipeline into routine care.
• Asia’s longevity test: more years, but can patients reach better health? Asia is ageing fast. Longer life will become a crisis if screening, prevention, digital tools and treatment pathways do not catch up.
• Insulin politics: when ideology collides with survival. Congress is again debating a broader $35 insulin cap. A life-sustaining medicine should not depend on a philosophy war over insurance markets.
• Primary care wants the money back. CMS wants to shift Medicare payment toward primary and preventive care. Every system says prevention matters. The budget usually says something else.p of stage IV lung-cancer patients whose disease is confined to the lungs. Old exclusion rules are being tested.

This is not another health news digest. It’s a twice-weekly readout of where evidence meets power and where power must turn into action.

---

Europe’s Parliament is reshuffling power. Will health make the cut?

Brussels is heading into the summer break, but the political bargaining has already begun. The European Parliament’s leadership roles run on two-and-a-half-year cycles, and the coming midterm reshuffle will decide who controls the presidency, vice-presidencies, committee chairs, vice-chairs and coordinator posts. These jobs are not decorative. They shape the files that will define Europe’s next phase: the pharmaceutical package, HTA, medical devices, EHDS, AI, research funding and the next EU budget. European Parliament, European Parliament Committees, Table.Media

The question is not only who gets the rooms, the titles or the votes. The question is whether health will be treated as a strategic portfolio, not a soft one. Europe does not lack health policy files. It lacks delivery discipline. Cancer outcomes remain unequal, diagnostics are still patchy, biomarker testing is too slow, clinical trials remain concentrated, and reimbursement delays keep turning science into waiting. Parliament may spend the summer deciding who gets the jobs. Patients will judge what those people do with them.

---

One assessment. Twenty-seven access clocks?

Europe’s health technology assessment system has moved from architecture to output. The Commission has published joint clinical assessment reports for tarlatamab and lurbinectedin, two orphan medicines for extensive-stage small cell lung cancer. Germany, Hungary and Portugal carried out the assessments under the EU HTA Regulation, all Member States endorsed them on 22 June, and the Commission says patients and clinical experts were consulted. That is real cooperation, and it deserves recognition. European Commission, Tarlatamab JCA, Lurbinectedin JCA

But publication is not patient access. The reports provide a common scientific analysis of relative clinical effects. They do not decide value, price or reimbursement, and those powers remain national. Europe may have reduced duplication without yet reducing delay. Small cell lung cancer moves quickly. Administrative systems rarely do. The HTA Regulation should not be judged by the number of reports uploaded to a website. It should be judged by whether common evidence becomes faster decisions, clearer requirements and fewer inequalities between patients.

---

Doctors must get their hands dirty

The most important exchange at Washington’s latest health hearing was not about another technical adjustment to vaccine policy. It was about whether a doctor appointed to lead a major public-health institution would confront political power when science is under pressure. Dr Erica Schwartz, nominated to lead the CDC, promised scientific integrity but repeatedly avoided a direct answer on how she would respond if ordered to pursue a policy contradicting evidence. Senator Bill Cassidy, himself a physician, pressed her on whether CDC leadership would stand up to vaccine misinformation and defend immunisation confidence. Reuters, The Guardian, Wall Street Journal

Doctors are often told to stay above politics. That is a comfortable myth. Screening programmes, vaccination policy, research budgets, regulatory decisions and access to innovation are all political choices. The white coat cannot become a hiding place. Personalised medicine faces the same test. The science may identify the right patient, biomarker and treatment, but implementation depends on professionals willing to engage with reimbursement, data governance, regulation and resistance. When evidence and patient safety are at stake, doctors must roll up their sleeves and get their hands dirty.

---

EU eases MDR burden for well-established medical devices

The European Commission has taken a targeted step toward a more proportionate Medical Devices Regulation, with two delegated acts expanding the list of well-established technologies eligible for simplified regulatory treatment. These are mature devices with stable designs, known safety and performance profiles, and long histories of clinical use. Certain implantable, class IIb and class III devices may be exempted from specific clinical investigation or technical-documentation assessment requirements. European Commission, RAPS

This is the right argument to have. Regulation should be tough where uncertainty is high and proportionate where technology is familiar. But simplification must not become deregulation by stealth. Manufacturers still need robust evidence, vigilance and post-market surveillance. The test is not whether paperwork gets lighter. The test is whether useful devices stay available without weakening patient safety. Europe is learning that regulatory credibility depends not only on rules, but on knowing when rules are doing work and when they are just creating drag.

---

The launch delay ate the approval

Celcuity won FDA approval for Revtorpyk, or gedatolisib, for certain patients with advanced HR-positive, HER2-negative breast cancer whose tumours do not carry a PIK3CA mutation. The trial result was strong: the combination reduced the risk of disease progression or death by 76%, with median progression-free survival of 9.3 monthscompared with 2.0 months for fulvestrant alone. But Celcuity shares fell nearly 19% after the company said launch would wait until the third quarter and investors focused on supply and label concerns, including severe mouth inflammation in 22% of patients on the three-drug regimen. Reuters

This is the whole issue in one market reaction. FDA approval is a major yes, but it is not the finish line. Supply, launch timing, toxicity management, clinician confidence, pricing and patient selection decide whether approval becomes care. The patient does not experience a press release. The patient experiences whether the drug is available, tolerable, funded and used at the right moment. Evidence opens the door. Implementation decides whether anyone walks through it.

---

Digital care met the fraud wall

CMS is proposing major changes to Medicare physician payment and remote monitoring rules, including tighter guardrails around remote patient monitoring and remote therapeutic monitoring. STAT reported that Medicare regulators want to prevent vendors from providing remote patient monitoring services on behalf of doctors, a change industry warned could be deeply disruptive. CMS’s wider proposed physician fee schedule also emphasises primary care, prevention, billing oversight and moving Medicare away from paying mainly for service volume. STAT, CMS, Reuters

Digital health has spent years selling itself as access, convenience and prevention. Fine. Now it has to prove it. Remote monitoring can catch deterioration early, support chronic care and keep patients out of hospital. It can also become a billing architecture wrapped in technology language. The next phase of digital care will not be won by devices alone. It will be won by evidence, accountability, workflow integration and payment rules that reward real clinical value rather than remote noise.

---

The biomarker said yes. The subsidy said wait.

Rare-cancer patients in Australia are paying up to A$60,000 while waiting for a broader PBS listing for Keytruda, after a positive PBAC recommendation for a pan-tumour approach. The policy shift would allow appropriate patients to access pembrolizumab based on clinical judgment and tumour biology rather than cancer type alone. But until negotiations and listing arrangements are complete, the gap between recommendation and subsidy remains very real for patients. The Australian, Rare Cancers Australia, Department of Health FOI

This is precision medicine hitting the reimbursement wall. The biomarker can say yes. The clinician can say yes. The advisory committee can say yes. But if the subsidy still says wait, patients are left with crowdfunding, savings, retirement money or nothing. Tumour-agnostic science is moving faster than tumour-specific funding systems. That is not a technical inconvenience. It is the difference between a molecular result that changes care and a molecular result that simply tells patients what they cannot afford.

---

Pipeline rich, pathway poor: Latin America’s real innovation test

Latin America does not have an innovation problem. It has an implementation problem. Bristol Myers Squibb’s regional leadership has highlighted more than 100 clinical trials across approximately 1,000 sites, involving about 3,800 patients, and expects to bring eight new medicines and 16 additional indications to Latin American patients by 2030. The science is moving. The pipeline is moving. The question is whether health systems can move with it.  BMS LATAM

Clinical trials and product launches are not enough if patients still lack timely diagnosis, biomarker testing, referral pathways, reimbursement, trained clinicians and treatment-ready hospitals. Latin America should not be treated merely as a recruitment base for global trials or a growth market for medicines. It should become an implementation region, where industry investment, diagnostics, financing, data systems and workforce readiness are designed together. A strong pipeline is not a victory if routine care remains pathway poor.

---

Asia’s longevity test: more years, but can patients reach better health?

Asia’s longevity revolution is becoming a health-system stress test. In 2024, the Asia-Pacific region was home to 721 million people aged 60 or over, roughly one in seven people. By 2050, that figure is projected to approach 1.3 billion, or one in four. Noncommunicable diseases caused 23 million deaths in Asia-Pacific in 2021, and the WHO South-East Asia Region recorded 2.37 million new cancer cases in 2022, with new cases projected to rise by 85.7% by 2050. A 2025 patient survey across Hong Kong, Indonesia, Malaysia and Singapore found that 55% often lacked the right information to make treatment decisions, while 38% first used digital tools, including AI, for treatment guidance. ESCAP, OECD and WHO, WHO South-East Asia, Prudential

Longer life is not automatically healthier life. The region needs prevention, risk assessment, screening, earlier diagnosis, continuous management and clearer patient navigation. Digital tools and AI may help, but they can also become a symptom of system failure when patients turn to them because they cannot find reliable human guidance. Personalised medicine should be central to the transition, but only if genomics, biomarkers, diagnostics and digital tools are connected to real pathways patients can understand and reach.

---

Insulin politics: when ideology collides with survival

A bipartisan Senate proposal would extend the $35 monthly insulin cap beyond Medicare to people with private insurance and create a pilot programme to improve access for uninsured patients. The measure passed the Senate health committee by 15 to 8, but its future remains tied to the familiar argument over whether government should intervene in private insurance markets. Around 8 million Americans rely on insulin, and AP has reported that about 57% of privately insured Americans are in self-insured plans beyond the reach of state caps. Axios, AP, American Diabetes Association

Insulin is not an optional consumer product. For many patients, it is survival measured in millilitres. A $35 cap will not fix list prices, rebates, PBM incentives, pumps, sensors or the wider economics of diabetes care. But complexity cannot become an alibi for paralysis. A system that forces patients to ration insulin is not functioning efficiently. It is transferring system failure directly onto the body of the patient.

---

Primary care wants the money back

CMS has proposed changes to Medicare’s physician payment system, saying the updates would support primary care, prevention, better coordination and more accurate payment. The proposal would update the Physician Fee Schedule, increase transparency around payment-rate calculations, strengthen billing oversight and move Medicare away from paying mainly for service volume. CMS also says the proposal would end traditional MIPS reporting in 2029 and shift clinicians toward more specialty-focused reporting pathways. CMS, Reuters

Every health system praises prevention. The budget often disagrees. Primary care is where risk is found early, chronic disease is managed, screening is made real and patients are kept from becoming expensive emergencies. But speeches about prevention do not pay clinicians, build teams or give practices time. If Medicare wants earlier intervention, it has to fund the front door of care, not just admire it from the hospital bill.

---

The Rest-of-July Watch

---

Follow the last-mile conversation!

IPM Alliance tracks the decisions, bottlenecks and implementation gaps shaping personalised medicine access. Follow us for briefings, events, policy signals and practical insights from across regions and disease areas.

• LinkedIn
• YouTube
• X

---

We want to hear from you

When a patient becomes eligible for personalised care, where does the system most often lose them: identification, testing, referral, reimbursement, delivery capacity or equity?

---

Know someone who should be reading this?

IPM Brief is built for people working where science, policy and patient access collide. If one colleague would find this useful, forward it to them and help bring them into the conversation.

---

International Alliance for Personalised Medicine

Avenue de l’Armée / Legerlaan 10, 1041 Brussels, Belgium

This email was sent to jayasinghtec29@gmail.com. You are receiving this email because you are part of the IPM Alliance network or have engaged with our activities, briefings, events, or policy work.